References
- Muller-Lissner S, Koch G, Talley NJ, Drossman D, Rueegg P, Dunger-Baldauf C, et al. Subject’s global assessment of relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 2003;56:310–6.
- Corazziari E, Bytzer P, Delvaux M, Holtmann G, Malagelada JR, Morris J, et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2003;18:569–80.
- Committee for proprietary medical products (CPMP). The European Agency for the Evaluation of Medicinal Products (EMEA)., Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. London; 2003 http:www.epa.govhttp://www.epa.gov http://www.epa.gov http://www.epa.gov http://www.epa.gov http://www.epa.gov http://www.epa.gov http://www.epa.gov http://www.epa.gov http://www.emea.eu.int/pdfs/human/ewp/078597en.pdf.
- Nyhlin H, Bang C, Elsborg L, Silvennoinen J, Holme I, Rüegg P, et al. A double-blind, placebo-controlled, randomised study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004;39:119–26.
- Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671–6.
- Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877–88.
- Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15: 1655–66.
- Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001;15:277–89.
- Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivityto rectal distension in healthy subjects. Aliment Pharmacol Ther 2003;17: 577–85.
- Kamm MA. Constipation and its management. Br Med J 2003; 327:459–60.
References
- Szostecki C, Guldner HH, Will H. Autoantibodies against ‘nuclear dots’ in primary biliary cirrhosis. Semin Liver Dis 1997; 17:71–8.
- Bogdanos DP, Baum H, Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis 2003;7:759–77.
- Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98:431–7.
- Vergani D, Bogdanos DP. Positive markers in AMA-negative PBC. Am J Gastroenterol 2003;98:241–3.
- Wichmann I, Montes-Cano MA, Respaldiza N, Alvarez A, Walter K, Franco E, et al. Clinical significance of anti-multiple nuclear dots/Sp100 autoantibodies. Scand J Gastroenterol 2003;38:996–9.
- Muratori P, Muratori L, Cassani F, Terlizzi P, Lenzi M, Rodrigo L, et al. Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol 2002;127:172–5.